Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

Impact · against what's priced in

The upgrade of Arbutus Biopharma to a Zacks Rank #2 (Buy) is a positive catalyst driven by an upward trend in consensus earnings estimates. This fundamental shift in the earnings outlook suggests near-term price appreciation potential.

ABUS+0.40: No priced-in read yet
In context: The stock has been upgraded to a Buy rating following an upward trend in earnings estimates from sell-side analysts.
Read from the article alone
Actual

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

healthcare
ABUS
biopharma
earnings estimates
equity research
stock upgrade

Search tags

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

What matters in this story

Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

What matters in this story

Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider

How each ticker is affected

Track these names every morning.

Do Options Traders Know Something About Harrow Stock We Don't?

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

What matters in this story

Next reads from the same story arc

Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

What matters in this story

Next reads from the same story arc

Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider

How each ticker is affected

Track these names every morning.

Do Options Traders Know Something About Harrow Stock We Don't?

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC